Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer | Synapse

July 13, 2005Open Access

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Shepherd et al. (Wed,) studied this question.

synapsesocial.com/papers/69deab246bae133e7de948b5 https://doi.org/https://doi.org/10.1056/nejmoa050753

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome2005 · 1,855 citations
2<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy2004 · 9,416 citations
3A sharper Bonferroni procedure for multiple tests of significance1988 · 4,744 citations
4Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials1996 · 2,517 citations
5Cancer Statistics, 20042004 · 4,003 citations